SlideShare a Scribd company logo
1 of 29
MULTIPLE DOSAGE REGIMEN
Presented by:
MD. MOHABBOT HOSSEN
B.Pharm (Hon’s)
Dhaka International University
INTRODUCTION
After single-dose drug administration, the plasma drug level
rises above and then falls below the minimum effective
concentration (MEC), resulting in a decline in therapeutic
effect.
To maintain prolonged therapeutic activity, many drugs
are given in a multiple-dosage regimen.
In calculating a multiple-dose regimen, the desired or target
plasma drug concentration must be related to a therapeutic
response, and the multiple-dose regimen must be designed
to produce plasma concentrations within the therapeutic
window.
• There are two main parameters that can be adjusted in
developing a dosage regimen:
1. The size of the drug dose.
2. The frequency of drug administration, ʈ (i.e, the time interval
between doses).
Dosage regimen
• Dosage regimen:
The frequency of administration of a drug in a particular dose is called as
Dosage regimen.
• For some drugs like analgesics single dose is efficient for optimal
therapeutic effect however the duration of most illnesses are longer
than the therapeutic effect produced by a single dose, In such cases
drugs are required to be taken on a repetitive bases over a period of time
depending upon the nature of illness.
Multiple Dosage Administrations:
Multiple dose administration refers to the administration of successive
dosage of drug in which a drug is administrated frequently with constant
dose interval. Both dose and dose interval on chosen for that-
The plasma drug concentration maintains with the therapeutic range.
 And to get the maximum therapeutic (clinical) effect.
Basic considerations for multiple dosage regimen (MDR)
Some basic consideration should be adjusted in developing a dosage
regimen.
1) Size of dose of the drug.
2) Frequency of drug administration (time interval between doses).
3) Successive doses of the drug.
4) Dose interval should be such that the drug does not leave the body
completely before the next dose.
5) Steady state concentration must be maintained between the MEC
and MTC level.
Contd..
6) Excessive fluctuation in drug level should not be allowed.
7) Drug should not be accumulated.
8) Desired plasma drug conc. must be related to therapeutic response.
9) Pharmacokinetic parameter should be obtained after single dose.
10) In MDR, it is necessary to decide whether successive does have any effect on
previous dose.
Example,
common drug give in MDR.
-Antibiotic (Ampicillin)
-Anticonvulsant (Phenobarbital, phenytoin
-Antiepileptic (phenytoin)
-Anticancers
-Antidiabetics (Insulin)
-Antiasthmatics
/Bronchodilator
(Theophylline)
-Cardiotonics digoxin)
-Contraceptives (Progestin)
(Hormone)
Purpose of multiple dose regimen
1. To maintain the plasma level within the therapeutic range.
2. To maintain the plasma level without excessive fluctuation and drug accumulation.
3. To maintain the maximum effective concentration (MEC).
4. To maintain the steady-state plasma and tissue drug conc. for the long term
management of disease.
5. To maintain the desired MTC (Antibiotic).
6. For achieving prolonged therapeutic activity.
7. Single dose is usually unsuitable to maintain the steady-state plasma drug conc. So
MDR is established.
8. For quickly metabolized drug (1st pass effect), MDR is necessary.
9. For prophylactic treatment of many disease.
10. To destroy the infected organism.
11. Narrow therapeutic index drugs may cause toxicity (phenytoin), in such cases
multiple dose is required.
MULTIPLE DOSING WITH RESPECT TO ORAL ROUTE
• When an oral multiple dosing regimen is followed, plasma conc. will
increase, reach a maximum and begin to decline. A 2nd dose will be
administered before all of the absorbed drug from 1st dose is
eliminated.
• Consequently plasma conc. resulting from 2nd dose will be higher
than from 1st dose. This increase in conc. with dose will continue to
occur until a steady state is reach at which rate of drug entry into the
body = rate of exit.
steady-state drug concentration
steady-state drug concentration:
steady-state drug concentration may be defined as the concentration in
which, the rate of drug entering the body (infusion rate) is equal to the
rate of drug leaving the body. So rate of change plasma drug conc. will
be "0" .
So, in steady-state,
rate of drug in = rate of drug out.
How it can be obtained?
1. The repetitive equal dose are given at a constant frequency
(interval).
2. Drug accumulation occurs and plasma drug conc. reach to a plateau
level.
3. Steady state concentration is obtained and drug conc. Fluctuate
within (Cmax and Cmin) and these remain unchanged from dose to
dose.
STEADY STATE CONCENTRATION
Principle of Superposition
• For calculation of multiple-dose regimens, it is necessary to decide
whether successive doses of drug will have any effect on the previous
dose.
• The principle of superposition assumes that early doses of drug do not
affect the pharmacokinetics of subsequent doses.
• Therefore, the blood levels after the second, third, or nth dose will
overlay or superimpose the blood level attained after the (n-1)th dose.
• At steady state
AUC (∫∞
0C pdt) = AUC(∫t2
t 1 C pdt)
Single dose Multiple dose
• The plasma drug concentrations after multiple doses may be
predicted from the plasma drug concentrations obtained after a single
dose.
• The predicted plasma drug concentration in the patient is the total
drug concentration obtained by adding the residual drug
concentration obtained after each previous dose.
Drug Accumulation
• If the drug is administered at a fixed dose and a fixed dosage interval,
as is the case with multiple-dose regimens, the amount of drug in the
body will increase and then plateau to a mean plasma level higher
than the peak C p obtained from the initial dose.
• When the second dose is given after a time interval shorter than the
time required to "completely" eliminate the previous dose, drug
accumulation will occur in the body.
• However, if the second dose is given after a time interval longer than
the time required to eliminate the previous dose, drug will not
accumulate.
• At steady state, the plasma drug levels fluctuate between Cmax and
Cmin.
• Once steady state is obtained, C ∞
max and C ∞
min are constant and
remain unchanged from dose to dose.
• The C ∞
max is important in determining drug safety.
• The C ∞
max should always remain below the minimum toxic
concentration.
• The C ∞
max is also a good indication of drug accumulation.
Accumulation Index (R)
Accumulation is affected by the elimination half-life of the drug and the
dosing interval. The index for measuring drug accumulation R is-
Substituting for Cmax after the first dose and at steady state yields-
• The above equation shows that drug accumulation measured with
the R index depends on the elimination constant and the dosing
interval and is independent of the dose.
• For a drug given in repetitive oral doses, the time required to reach
steady state is dependent on the elimination half-life of the drug and
is independent of the size of the dose, the length of the dosing
interval, and the number of doses.
Accumulation Half-life
An equation for the estimation of the time to reach one-half of the steady-
state plasma levels or the accumulation half-life has been described by van
Rossum and Tomey (1968).
For IV administration, k a is very rapid (approaches ∞); k is very small in
comparison to k a and can be omitted in the denominator of the above
equation. Thus, the above equation reduces to-
Since ka/ka = 1 and log 1 = 0, so the accumulation t1/2 is directly
proportional to the elimination t1/2.
Repetitive Intravenous Injections
• The maximum amount of drug in the body following a single rapid IV
injection is equal to the dose of the drug.
• If Ƭ is equal to the dosage interval then the amount of drug remaining in the
body after several hours can be determined with –
• The fraction ( f ) of the dose remaining in the body is related to the
elimination constant (k) and the dosage interval (Ƭ) as follows:
Another parameters following repetitive injection-
1. maximum amount of drug in the body at steady state conc.
2. minimum amounts of drug in the body at steady state
Dmin = Dmax – D0
EXAMPLES
A patient receives 1000 mg every 6 hours by repetitive IV injection of
an antibiotic with an elimination half-life of 3 hours. Assume the drug is
distributed according to a one-compartment model and the volume of
distribution is 20 L.
a. Find the maximum and minimum amounts of drug in the body.
a. Here,
LOADING DOSE
• Since extravascular doses require time for absorption into the plasma
to occur, therapeutic effects are delayed until sufficient plasma
concentrations are achieved.
• To reduce the onset time of the drug that is, the time it takes to
achieve the minimum effective concentration a loading (priming) or
initial dose of drug is given.
• The main objective of the loading dose is to achieve desired plasma
concentrations as quickly as possible.
LOADING DOSE
So, The "loading dose" is one or a series of doses that may be given at the
onset of therapy with the aim of achieving the target concentration rapidly.
Loading dose = Vd x TC/F
Vd = Volume of distribution
TC = Target concentration
F = Fraction of dose
• For most drug loading dose can be given as single dose by the chosen route
of administration.
• Loading doses tend to be large, and they are often given parenterally and
rapidly.
Bioequivalence
Bioequivalence is defined as the absence of a significant difference in
the rate and extent to which the active ingredient or active moiety in
pharmaceutical equivalents or pharmaceutical alternatives becomes
available at the site of drug action when administered at the same
molar dose under similar conditions in an appropriately designed study.
Multiple Dosage regimen

More Related Content

What's hot

Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenKLE College of pharmacy
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing BioavailabilityDibrugarh University
 
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)DR. METI.BHARATH KUMAR
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kineticsSujit Patel
 
one compartment model ppt
one compartment model pptone compartment model ppt
one compartment model pptSheetal Jha
 
P h partition hypothesis
P h partition hypothesisP h partition hypothesis
P h partition hypothesisZahid1392
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALSDivya Pushp
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalenceNaresh Gorantla
 
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)DR. METI.BHARATH KUMAR
 
Application of pharmacokinetics
Application of pharmacokineticsApplication of pharmacokinetics
Application of pharmacokineticsChristy George
 

What's hot (20)

Pharmacokinetic models
Pharmacokinetic  modelsPharmacokinetic  models
Pharmacokinetic models
 
Dosage regimen
Dosage regimenDosage regimen
Dosage regimen
 
Pharmacokinetic models
Pharmacokinetic modelsPharmacokinetic models
Pharmacokinetic models
 
Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimen
 
Bio availability and bio equivalence
Bio availability and bio equivalenceBio availability and bio equivalence
Bio availability and bio equivalence
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing Bioavailability
 
Multicompartment Models
Multicompartment ModelsMulticompartment Models
Multicompartment Models
 
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)
WAGNER NELSON METHOD (Contact me: dr.m.bharathkumar@gmail.com)
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kinetics
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
 
one compartment model ppt
one compartment model pptone compartment model ppt
one compartment model ppt
 
Pharmacokinetic models
Pharmacokinetic modelsPharmacokinetic models
Pharmacokinetic models
 
P h partition hypothesis
P h partition hypothesisP h partition hypothesis
P h partition hypothesis
 
Non linear pharmacokinetics
Non linear pharmacokineticsNon linear pharmacokinetics
Non linear pharmacokinetics
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALS
 
Dissolution
DissolutionDissolution
Dissolution
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalence
 
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
 
Bioequivalence protocol
Bioequivalence  protocolBioequivalence  protocol
Bioequivalence protocol
 
Application of pharmacokinetics
Application of pharmacokineticsApplication of pharmacokinetics
Application of pharmacokinetics
 

Similar to Multiple Dosage regimen

Biopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensBiopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensSonia Barua
 
Multiple Dosage Oral Administration/ Dosage Regimen
Multiple Dosage Oral Administration/ Dosage Regimen Multiple Dosage Oral Administration/ Dosage Regimen
Multiple Dosage Oral Administration/ Dosage Regimen Nausheen Fatima
 
6-Plasma Half Life and factor affecting.pptx
6-Plasma Half Life and factor affecting.pptx6-Plasma Half Life and factor affecting.pptx
6-Plasma Half Life and factor affecting.pptxbilaliqbal02
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parametersDeepakPandey379
 
Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring wadalshigil84
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoringDr Sajeena Jose
 
Advanced Drug Delivery System
Advanced Drug Delivery SystemAdvanced Drug Delivery System
Advanced Drug Delivery SystemJalal Uddin
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusionDr.saqib habib
 
BP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxBP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxAlka Maral
 
01Introduction SRDDS AND CRDDS.pptx
01Introduction SRDDS AND CRDDS.pptx01Introduction SRDDS AND CRDDS.pptx
01Introduction SRDDS AND CRDDS.pptxPadmineePatil
 
SUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSonam Gandhi
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptxMuhannadOmer
 

Similar to Multiple Dosage regimen (20)

Biopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimensBiopharmaceutics: Multiple dosage regimens
Biopharmaceutics: Multiple dosage regimens
 
Multiple Dosage Oral Administration/ Dosage Regimen
Multiple Dosage Oral Administration/ Dosage Regimen Multiple Dosage Oral Administration/ Dosage Regimen
Multiple Dosage Oral Administration/ Dosage Regimen
 
Kinetics of multiple dosing
Kinetics of multiple dosingKinetics of multiple dosing
Kinetics of multiple dosing
 
THERAPUTIC REGIMEN.pptx
THERAPUTIC REGIMEN.pptxTHERAPUTIC REGIMEN.pptx
THERAPUTIC REGIMEN.pptx
 
6-Plasma Half Life and factor affecting.pptx
6-Plasma Half Life and factor affecting.pptx6-Plasma Half Life and factor affecting.pptx
6-Plasma Half Life and factor affecting.pptx
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parameters
 
dosage regimen.pptx
dosage regimen.pptxdosage regimen.pptx
dosage regimen.pptx
 
Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring Therapeutic Drugs Monitoring
Therapeutic Drugs Monitoring
 
Half life ppt
Half life pptHalf life ppt
Half life ppt
 
multiple-dosage-regimen.pdf
multiple-dosage-regimen.pdfmultiple-dosage-regimen.pdf
multiple-dosage-regimen.pdf
 
Pharmacokinetic
PharmacokineticPharmacokinetic
Pharmacokinetic
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
 
Advanced Drug Delivery System
Advanced Drug Delivery SystemAdvanced Drug Delivery System
Advanced Drug Delivery System
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusion
 
BP 604T unit 3 notes.docx
BP 604T unit 3 notes.docxBP 604T unit 3 notes.docx
BP 604T unit 3 notes.docx
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
 
01Introduction SRDDS AND CRDDS.pptx
01Introduction SRDDS AND CRDDS.pptx01Introduction SRDDS AND CRDDS.pptx
01Introduction SRDDS AND CRDDS.pptx
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
SUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power pointSUSTAINDRUG DELIVERY SYSTEMS power point
SUSTAINDRUG DELIVERY SYSTEMS power point
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptx
 

Recently uploaded

EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfMr Bounab Samir
 
Quarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayQuarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayMakMakNepo
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxChelloAnnAsuncion2
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationAadityaSharma884161
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxEyham Joco
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxLigayaBacuel1
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxsqpmdrvczh
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementmkooblal
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfphamnguyenenglishnb
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfUjwalaBharambe
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 

Recently uploaded (20)

EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
 
Quarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayQuarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up Friday
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint Presentation
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptx
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptx
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptx
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of management
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 

Multiple Dosage regimen

  • 1. MULTIPLE DOSAGE REGIMEN Presented by: MD. MOHABBOT HOSSEN B.Pharm (Hon’s) Dhaka International University
  • 2. INTRODUCTION After single-dose drug administration, the plasma drug level rises above and then falls below the minimum effective concentration (MEC), resulting in a decline in therapeutic effect. To maintain prolonged therapeutic activity, many drugs are given in a multiple-dosage regimen. In calculating a multiple-dose regimen, the desired or target plasma drug concentration must be related to a therapeutic response, and the multiple-dose regimen must be designed to produce plasma concentrations within the therapeutic window.
  • 3. • There are two main parameters that can be adjusted in developing a dosage regimen: 1. The size of the drug dose. 2. The frequency of drug administration, ʈ (i.e, the time interval between doses).
  • 4. Dosage regimen • Dosage regimen: The frequency of administration of a drug in a particular dose is called as Dosage regimen. • For some drugs like analgesics single dose is efficient for optimal therapeutic effect however the duration of most illnesses are longer than the therapeutic effect produced by a single dose, In such cases drugs are required to be taken on a repetitive bases over a period of time depending upon the nature of illness. Multiple Dosage Administrations: Multiple dose administration refers to the administration of successive dosage of drug in which a drug is administrated frequently with constant dose interval. Both dose and dose interval on chosen for that- The plasma drug concentration maintains with the therapeutic range.  And to get the maximum therapeutic (clinical) effect.
  • 5. Basic considerations for multiple dosage regimen (MDR) Some basic consideration should be adjusted in developing a dosage regimen. 1) Size of dose of the drug. 2) Frequency of drug administration (time interval between doses). 3) Successive doses of the drug. 4) Dose interval should be such that the drug does not leave the body completely before the next dose. 5) Steady state concentration must be maintained between the MEC and MTC level.
  • 6. Contd.. 6) Excessive fluctuation in drug level should not be allowed. 7) Drug should not be accumulated. 8) Desired plasma drug conc. must be related to therapeutic response. 9) Pharmacokinetic parameter should be obtained after single dose. 10) In MDR, it is necessary to decide whether successive does have any effect on previous dose. Example, common drug give in MDR. -Antibiotic (Ampicillin) -Anticonvulsant (Phenobarbital, phenytoin -Antiepileptic (phenytoin) -Anticancers -Antidiabetics (Insulin) -Antiasthmatics /Bronchodilator (Theophylline) -Cardiotonics digoxin) -Contraceptives (Progestin) (Hormone)
  • 7. Purpose of multiple dose regimen 1. To maintain the plasma level within the therapeutic range. 2. To maintain the plasma level without excessive fluctuation and drug accumulation. 3. To maintain the maximum effective concentration (MEC). 4. To maintain the steady-state plasma and tissue drug conc. for the long term management of disease. 5. To maintain the desired MTC (Antibiotic). 6. For achieving prolonged therapeutic activity. 7. Single dose is usually unsuitable to maintain the steady-state plasma drug conc. So MDR is established. 8. For quickly metabolized drug (1st pass effect), MDR is necessary. 9. For prophylactic treatment of many disease. 10. To destroy the infected organism. 11. Narrow therapeutic index drugs may cause toxicity (phenytoin), in such cases multiple dose is required.
  • 8. MULTIPLE DOSING WITH RESPECT TO ORAL ROUTE • When an oral multiple dosing regimen is followed, plasma conc. will increase, reach a maximum and begin to decline. A 2nd dose will be administered before all of the absorbed drug from 1st dose is eliminated. • Consequently plasma conc. resulting from 2nd dose will be higher than from 1st dose. This increase in conc. with dose will continue to occur until a steady state is reach at which rate of drug entry into the body = rate of exit.
  • 9. steady-state drug concentration steady-state drug concentration: steady-state drug concentration may be defined as the concentration in which, the rate of drug entering the body (infusion rate) is equal to the rate of drug leaving the body. So rate of change plasma drug conc. will be "0" . So, in steady-state, rate of drug in = rate of drug out.
  • 10. How it can be obtained? 1. The repetitive equal dose are given at a constant frequency (interval). 2. Drug accumulation occurs and plasma drug conc. reach to a plateau level. 3. Steady state concentration is obtained and drug conc. Fluctuate within (Cmax and Cmin) and these remain unchanged from dose to dose.
  • 12. Principle of Superposition • For calculation of multiple-dose regimens, it is necessary to decide whether successive doses of drug will have any effect on the previous dose. • The principle of superposition assumes that early doses of drug do not affect the pharmacokinetics of subsequent doses. • Therefore, the blood levels after the second, third, or nth dose will overlay or superimpose the blood level attained after the (n-1)th dose. • At steady state AUC (∫∞ 0C pdt) = AUC(∫t2 t 1 C pdt) Single dose Multiple dose
  • 13.
  • 14. • The plasma drug concentrations after multiple doses may be predicted from the plasma drug concentrations obtained after a single dose. • The predicted plasma drug concentration in the patient is the total drug concentration obtained by adding the residual drug concentration obtained after each previous dose.
  • 15.
  • 16. Drug Accumulation • If the drug is administered at a fixed dose and a fixed dosage interval, as is the case with multiple-dose regimens, the amount of drug in the body will increase and then plateau to a mean plasma level higher than the peak C p obtained from the initial dose. • When the second dose is given after a time interval shorter than the time required to "completely" eliminate the previous dose, drug accumulation will occur in the body. • However, if the second dose is given after a time interval longer than the time required to eliminate the previous dose, drug will not accumulate.
  • 17.
  • 18. • At steady state, the plasma drug levels fluctuate between Cmax and Cmin. • Once steady state is obtained, C ∞ max and C ∞ min are constant and remain unchanged from dose to dose. • The C ∞ max is important in determining drug safety. • The C ∞ max should always remain below the minimum toxic concentration. • The C ∞ max is also a good indication of drug accumulation.
  • 19. Accumulation Index (R) Accumulation is affected by the elimination half-life of the drug and the dosing interval. The index for measuring drug accumulation R is- Substituting for Cmax after the first dose and at steady state yields-
  • 20. • The above equation shows that drug accumulation measured with the R index depends on the elimination constant and the dosing interval and is independent of the dose. • For a drug given in repetitive oral doses, the time required to reach steady state is dependent on the elimination half-life of the drug and is independent of the size of the dose, the length of the dosing interval, and the number of doses.
  • 21. Accumulation Half-life An equation for the estimation of the time to reach one-half of the steady- state plasma levels or the accumulation half-life has been described by van Rossum and Tomey (1968). For IV administration, k a is very rapid (approaches ∞); k is very small in comparison to k a and can be omitted in the denominator of the above equation. Thus, the above equation reduces to- Since ka/ka = 1 and log 1 = 0, so the accumulation t1/2 is directly proportional to the elimination t1/2.
  • 22. Repetitive Intravenous Injections • The maximum amount of drug in the body following a single rapid IV injection is equal to the dose of the drug. • If Ƭ is equal to the dosage interval then the amount of drug remaining in the body after several hours can be determined with – • The fraction ( f ) of the dose remaining in the body is related to the elimination constant (k) and the dosage interval (Ƭ) as follows:
  • 23. Another parameters following repetitive injection- 1. maximum amount of drug in the body at steady state conc. 2. minimum amounts of drug in the body at steady state Dmin = Dmax – D0
  • 24. EXAMPLES A patient receives 1000 mg every 6 hours by repetitive IV injection of an antibiotic with an elimination half-life of 3 hours. Assume the drug is distributed according to a one-compartment model and the volume of distribution is 20 L. a. Find the maximum and minimum amounts of drug in the body.
  • 26. LOADING DOSE • Since extravascular doses require time for absorption into the plasma to occur, therapeutic effects are delayed until sufficient plasma concentrations are achieved. • To reduce the onset time of the drug that is, the time it takes to achieve the minimum effective concentration a loading (priming) or initial dose of drug is given. • The main objective of the loading dose is to achieve desired plasma concentrations as quickly as possible.
  • 27. LOADING DOSE So, The "loading dose" is one or a series of doses that may be given at the onset of therapy with the aim of achieving the target concentration rapidly. Loading dose = Vd x TC/F Vd = Volume of distribution TC = Target concentration F = Fraction of dose • For most drug loading dose can be given as single dose by the chosen route of administration. • Loading doses tend to be large, and they are often given parenterally and rapidly.
  • 28. Bioequivalence Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.